Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
BIO Stock Overview
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation.
BIOTON Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł4.02 |
52 Week High | zł5.67 |
52 Week Low | zł3.29 |
Beta | 0.27 |
1 Month Change | -2.55% |
3 Month Change | 2.69% |
1 Year Change | -21.58% |
3 Year Change | -6.63% |
5 Year Change | -36.77% |
Change since IPO | -96.74% |
Recent News & Updates
We Think BIOTON (WSE:BIO) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
The Strong Earnings Posted By BIOTON (WSE:BIO) Are A Good Indication Of The Strength Of The Business
Even though BIOTON S.A.'s ( WSE:BIO ) recent earnings release was robust, the market didn't seem to notice. We think...
Shareholder Returns
BIO | PL Biotechs | PL Market | |
---|---|---|---|
7D | 0.9% | -0.1% | 0.9% |
1Y | -21.6% | -37.4% | -23.7% |
Return vs Industry: BIO exceeded the Polish Biotechs industry which returned -38.9% over the past year.
Return vs Market: BIO underperformed the Polish Market which returned -14.5% over the past year.
Price Volatility
BIO volatility | |
---|---|
BIO Average Weekly Movement | 13.6% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 7.8% |
10% most volatile stocks in PL Market | 15.0% |
10% least volatile stocks in PL Market | 5.1% |
Stable Share Price: BIO is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: BIO's weekly volatility has increased from 7% to 14% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 392 | Jeremy Launders | https://www.bioton.pl |
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities.
BIOTON Fundamentals Summary
BIO fundamental statistics | |
---|---|
Market Cap | zł344.74m |
Earnings (TTM) | zł21.93m |
Revenue (TTM) | zł212.23m |
15.7x
P/E Ratio1.6x
P/S RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIO income statement (TTM) | |
---|---|
Revenue | zł212.23m |
Cost of Revenue | zł120.38m |
Gross Profit | zł91.86m |
Other Expenses | zł69.93m |
Earnings | zł21.93m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Aug 31, 2022
Earnings per share (EPS) | 0.26 |
Gross Margin | 43.28% |
Net Profit Margin | 10.33% |
Debt/Equity Ratio | 16.6% |
How did BIO perform over the long term?
See historical performance and comparisonValuation
Is BIOTON undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
15.72x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BIO's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BIO is good value based on its PE Ratio (15.7x) compared to the Polish Biotechs industry average (40.2x).
PE vs Market: BIO is poor value based on its PE Ratio (15.7x) compared to the Polish market (10.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIO is good value based on its PB Ratio (0.6x) compared to the PL Biotechs industry average (4.6x).
Future Growth
How is BIOTON forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
42.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOTON has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has BIOTON performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
38.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO has high quality earnings.
Growing Profit Margin: BIO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BIO has become profitable over the past 5 years, growing earnings by 38.9% per year.
Accelerating Growth: BIO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BIO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: BIO's Return on Equity (3.5%) is considered low.
Financial Health
How is BIOTON's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: BIO's short term assets (PLN167.8M) exceed its short term liabilities (PLN147.8M).
Long Term Liabilities: BIO's short term assets (PLN167.8M) exceed its long term liabilities (PLN95.5M).
Debt to Equity History and Analysis
Debt Level: BIO's net debt to equity ratio (14.8%) is considered satisfactory.
Reducing Debt: BIO's debt to equity ratio has reduced from 24.5% to 16.6% over the past 5 years.
Debt Coverage: BIO's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BIO's interest payments on its debt are well covered by EBIT (19.6x coverage).
Balance Sheet
Dividend
What is BIOTON current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BIO has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
5.9yrs
Average board tenure
CEO
Jeremy Launders
1.58yrs
Tenure
zł488,000
Compensation
Mr. Jeremy Launders has been President of the Management Board at BIOTON S.A. since October 30, 2020.
Board Members
Experienced Board: BIO's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
BIOTON S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: BIOTON S.A.
- Ticker: BIO
- Exchange: WSE
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł344.745m
- Shares outstanding: 85.86m
- Website: https://www.bioton.pl
Number of Employees
Location
- BIOTON S.A.
- ul. Poznanska 12
- Macierzysz
- Ozarów Mazowiecki
- 05-850
- Poland
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/18 00:00 |
End of Day Share Price | 2022/05/18 00:00 |
Earnings | 2021/09/30 |
Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.